Cargando…

T-cell agonists in cancer immunotherapy

Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yeonjoo, Shi, Yaoyao, Haymaker, Cara L, Naing, Aung, Ciliberto, Gennaro, Hajjar, Joud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537335/
https://www.ncbi.nlm.nih.gov/pubmed/33020242
http://dx.doi.org/10.1136/jitc-2020-000966
_version_ 1783590654482317312
author Choi, Yeonjoo
Shi, Yaoyao
Haymaker, Cara L
Naing, Aung
Ciliberto, Gennaro
Hajjar, Joud
author_facet Choi, Yeonjoo
Shi, Yaoyao
Haymaker, Cara L
Naing, Aung
Ciliberto, Gennaro
Hajjar, Joud
author_sort Choi, Yeonjoo
collection PubMed
description Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials.
format Online
Article
Text
id pubmed-7537335
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-75373352020-10-07 T-cell agonists in cancer immunotherapy Choi, Yeonjoo Shi, Yaoyao Haymaker, Cara L Naing, Aung Ciliberto, Gennaro Hajjar, Joud J Immunother Cancer Review Cancer cells can evade immune surveillance in the body. However, immune checkpoint inhibitors can interrupt this evasion and enhance the antitumor activity of T cells. Other mechanisms for promoting antitumor T-cell function are the targeting of costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator and glucocorticoid-induced tumor necrosis factor receptor. In addition, CD40 targets the modulation of the activation of antigen-presenting cells, which ultimately leads to T-cell activation. Agonists of these costimulatory molecules have demonstrated promising results in preclinical and early-phase trials and are now being tested in ongoing clinical trials. In addition, researchers are conducting trials of combinations of such immune modulators with checkpoint blockade, radiotherapy and cytotoxic chemotherapeutic drugs in patients with advanced tumors. This review gives a comprehensive picture of the current knowledge of T-cell agonists based on their use in recent and ongoing clinical trials. BMJ Publishing Group 2020-10-05 /pmc/articles/PMC7537335/ /pubmed/33020242 http://dx.doi.org/10.1136/jitc-2020-000966 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Review
Choi, Yeonjoo
Shi, Yaoyao
Haymaker, Cara L
Naing, Aung
Ciliberto, Gennaro
Hajjar, Joud
T-cell agonists in cancer immunotherapy
title T-cell agonists in cancer immunotherapy
title_full T-cell agonists in cancer immunotherapy
title_fullStr T-cell agonists in cancer immunotherapy
title_full_unstemmed T-cell agonists in cancer immunotherapy
title_short T-cell agonists in cancer immunotherapy
title_sort t-cell agonists in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537335/
https://www.ncbi.nlm.nih.gov/pubmed/33020242
http://dx.doi.org/10.1136/jitc-2020-000966
work_keys_str_mv AT choiyeonjoo tcellagonistsincancerimmunotherapy
AT shiyaoyao tcellagonistsincancerimmunotherapy
AT haymakercaral tcellagonistsincancerimmunotherapy
AT naingaung tcellagonistsincancerimmunotherapy
AT cilibertogennaro tcellagonistsincancerimmunotherapy
AT hajjarjoud tcellagonistsincancerimmunotherapy